Inventor · disambiguated record
Edgar G. Engleman
Also filed as: ENGLEMAN EDGAR · ENGLEMAN EDGAR G · ENGLEMAN EDGAR GEORGE
42 granted patents·37 pending applications·909 citations·filing 1982–2025
98Inventor score
Files withUNIV LELAND STANFORD JUNIOR44BOLT BIOTHERAPEUTICS INC8GODFREY WAYNE5IMMUNEDGE INC3LUMEN THERAPEUTICS LLC3
Top patents by PatentIndex Score
79 records- 0197US4634666AHuman-murine hybridoma fusion partnerUNIV LELAND STANFORD JUNIOR·Filed 1984·Granted Jan 6, 1987·338 cites·14 claims
- 0295US10272070B2Method for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Apr 30, 2019·11 cites·14 claims
- 0395US7557087B2Compositions and methods for treating diseasesLUMEN THERAPEUTICS LLC·Filed 2007·Granted Jul 7, 2009·36 cites·23 claims
- 0494US10583125B2Method for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Mar 10, 2020·8 cites·12 claims
- 0592US11110178B2Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Sep 7, 2021·3 cites·30 claims
- 0692US6528623B2Antibodies that specifically bind ACT-4-L-h-1 ligandUNIV LELAND STANFORD JUNIOR·Filed 2001·Granted Mar 4, 2003·33 cites·8 claims
- 0791US10851066B22-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Dec 1, 2020·2 cites·5 claims
- 0891US10675358B2Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Jun 9, 2020·5 cites·30 claims
- 0991US7098184B2Method of treating rheumatoid arthritis and multiple sclerosis diseases of the human immune systemUNIV LELAND STANFORD JUNIOR·Filed 2002·Granted Aug 29, 2006·27 cites·3 claims
- 1090US6528055B2Methods of administering antibodies that specifically bind ACT-4-L-h-1 ligandUNIV LELAND STANFORD JUNIOR·Filed 2001·Granted Mar 4, 2003·22 cites·23 claims
- 1189US5821332AReceptor on the surface of activated CD4+ T-cells: ACT-4UNIV LELAND STANFORD JUNIOR·Filed 1993·Granted Oct 13, 1998·51 cites·7 claims
- 1288US2025032459A1Method for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1387US10653669B2Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammationUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted May 19, 2020·5 cites·3 claims
- 1486US8629115B2Compositions and methods for treating diseasesROTHBARD JONATHAN B·Filed 2010·Granted Jan 14, 2014·3 cites·5 claims
- 1586US7364733B2Antibody to receptor on the surface of activated T-cells: ACT-4UNIV LELAND STANFORD JUNIOR·Filed 2004·Granted Apr 29, 2008·15 cites·10 claims
- 1684US9220744B2Compositions and methods for treating diseasesLUMEN THERAPEUTICS LLC·Filed 2014·Granted Dec 29, 2015·2 cites·5 claims
- 1784US7820626B2Compositions and methods for treating diseasesLUMEN THERAPEUTICS LLC·Filed 2008·Granted Oct 26, 2010·2 cites·5 claims
- 1884US6423539B2Adjuvant treatment by in vivo activation of dendritic cellsUNIV LELAND STANFORD JUNIOR·Filed 2001·Granted Jul 23, 2002·36 cites·19 claims
- 1984US6277962B1Receptor on the surface of activated t-cells: act-4UNIV LELAND STANFORD JUNIOR·Filed 1995·Granted Aug 21, 2001·40 cites·13 claims
- 2083US6242566B1Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cellsUNIV LELAND STANFORD JUNIOR·Filed 1994·Granted Jun 5, 2001·27 cites·40 claims
- 2180US5415874ANatural killer cell lines and clones with antigen specificityUNIV LELAND STANFORD JUNIOR·Filed 1989·Granted May 16, 1995·74 cites·14 claims
- 2279US7125670B2Ligand (ACT-4-L) to a receptor on the surface of activated CD4+T-cellsUNIV LELAND STANFORD JUNIOR·Filed 2002·Granted Oct 24, 2006·6 cites·14 claims
- 2378US2023113240A1Methods for cancer treatmentUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2478US2024245646A1Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammationUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 2577US2025388687A1Epo receptor agonists and antagonistsIMMUNEDGE INC·Filed 2025·Application pending·0 cites
- 2676US11547842B2Methods for cancer treatmentUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Jan 10, 2023·1 cites·11 claims
- 2776US6156878ALigand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cellsUNIV LELAND STANFORD JUNIOR·Filed 1997·Granted Dec 5, 2000·21 cites·6 claims
- 2875US2023111340A1Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2974US11547761B1Antibody adjuvant conjugatesUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jan 10, 2023·0 cites·91 claims
- 3072US11111217B22-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Sep 7, 2021·0 cites·3 claims
- 3172US2021283108A1Method for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3271US10966962B2Method for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Apr 6, 2021·0 cites·20 claims
- 3370US6821778B1Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cellsUNIV LELAND STANFORD JUNIOR·Filed 1996·Granted Nov 23, 2004·45 cites·11 claims
- 3470US2025129147A1Epo receptor agonists and antagonistsIMMUNEDGE INC·Filed 2023·Application pending·0 cites
- 3570US2025129170A1Epo receptor agonists and antagonistsIMMUNEDGE INC·Filed 2023·Application pending·0 cites
- 3669US10549082B2Methods for cancer treatmentUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Feb 4, 2020·3 cites·11 claims
- 3769US4777245ANon-human primate monoclonal antibodies and methodsGENELABS INC·Filed 1985·Granted Oct 11, 1988·24 cites·9 claims
- 3868US11400164B2Immunoconjugates targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2021·Granted Aug 2, 2022·0 cites·44 claims
- 3968US2009069535A1Ligand (ACT-4-L) to a Receptor on the Surface of Activated CD4+ T-CellsGODFREY WAYNE·Filed 2008·Application pending·0 cites
- 4066US2022347311A1Immunoconjugates Targeting HER2BOLT BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4165US2024368271A1Targeting GPR65 for the Treatment of Cancer in Overweight and Obese IndividualsUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 4264US2021059985A1Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammationUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 4363US2005192210A1Compositions and methods for treating diseasesFiled 2005·Application pending·0 cites
- 4463US2007092511A1Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cellsGODFREY WAYNE·Filed 2006·Application pending·0 cites
- 4562US12195432B22-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseasesUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Jan 14, 2025·0 cites·12 claims
- 4662US2009004295A1Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune responseKUEHNE FRIEDRICH W·Filed 2008·Application pending·0 cites
- 4762US2006217531A1Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cellsGODFREY WAYNE·Filed 2006·Application pending·0 cites
- 4861US2007077247A1Receptor on the surface of activated T-cells: ACT-4GODFREY WAYNE·Filed 2006·Application pending·0 cites
- 4959US10039751B2Reversing intestinal inflammation by inhibiting retinoic acid metabolismUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Aug 7, 2018·0 cites·20 claims
- 5057US2004136995A1Receptor on the surface of activated T-cells: ACT-4Filed 2004·Application pending·0 cites
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Edgar G. Engleman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →